Top Markets
#1 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +585.95%
#2 Phala Phala +86.06%
#3 Bitway Bitway +35.59%
#4 龙虾 (Lobster) 龙虾 (Lobster) +27.08%
#5 Backpack Backpack +25.83%
#6 ARK ARK +24.61%
#7 Mubarak Mubarak +24.07%
#8 Aerodrome Finance Aerodrome Finance +23.48%
#9 APEX APEX +21.77%
#10 The Black Bull The Black Bull +20.57%
Coin of the day
Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain)
Cài đặt
Ngôn ngữ
TIếNG VIệT
Tiền tệ
USD
Chủ đề
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Xếp hạng trong cổ phiếu #36735
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to... Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Giá cổ phiếu
$0.2483
Đồng bộ lần cuối: 2026-07-31
Vốn hóa thị trường
$2.30M
Thay đổi (1 ngày)
-3.39%
Thay đổi (1 năm)
-89.01%
Quốc gia
US
Giao dịch Ensysce Biosciences, Inc. (ENSC)

Danh mục

Healthcare
Lịch sử giá cổ phiếu của Ensysce Biosciences, Inc. (ENSC)
Giá đóng cửa cao nhất: $0.27 vào 2026-07-01

Giá đóng cửa thấp nhất: $34.45K vào 2018-03-01
Lịch sử giá cổ phiếu của Ensysce Biosciences, Inc. từ 2018 đến 2026
Hiệu suất giá cổ phiếu hàng năm
Năm Hiệu suất
2026 (TTM) -30.08%
2025 -82.94%
2024 -51.31%
2023 -92.24%
2022 -98.38%
2021 -70.28%
2020 13.26%
2019 5.39%
2018 0.00%
Giá cổ phiếu của các công ty hoặc đối thủ tương tự
Công ty Giá cổ phiếu Thay đổi 1năm% Quốc gia
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $527.10 38.03%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $198.16 705.18%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $959.70 34.96%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $124.39 -3.92%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $738.46 13.99%
CH